Paragon Care Limited (ASX:PGC)

Market Cap	273.13M -59.3%
Revenue (ttm)	3.67B +8.5%
Net Income	-13.93M
EPS	-0.01
Shares Out	1.66B
PE Ratio	n/a
Forward PE	10.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	754,665
Open	0.1400
Previous Close	0.1350
Day's Range	0.1400 - 0.1650
52-Week Range	0.1250 - 0.4100
Beta	-0.32
Analysts	Buy
Price Target	0.25 (+51.52%)
Earnings Date	Oct 4, 2026

About Paragon Care

Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohematology laboratories; offers ophthalmology and optometry, neonatal vision screening solutions, and procedural kits. It also provides neonatal and paediatric assessment, including newborn hearing and vision screening, jaundice management, NICU video monitoring, brain monitoring, b...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2005
• Employees: 550
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PGC

Financial Performance

In fiscal year 2025, Paragon Care's revenue was 3.61 billion, an increase of 21.68% compared to the previous year's 2.97 billion. Earnings were 20.57 million, an increase of 151.52%.

Analyst Summary

According to 2 analysts, the average rating for PGC stock is "Buy." The 12-month stock price target is $0.25, which is an increase of 51.52% from the latest price.

Price Target

$0.25

(51.52% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 1, 2026

Data Sources Report a data error